The billion-dollar gamble: Biotech CEO takes a risky second shot at an Alzheimer’s drug
The executives packed into the room, eager to hear the good news on their blockbuster-to-be. Medivation, a California startup, was developing a treatment for Alzheimer’s disease, and pivotal results from a major clinical trial were finally available. An earlier study, conducted in Russia, had generated what Alzheimer’s experts hailed as the best results the field had…
Utah Standard News depends on the support of readers like you.
Good Journalism requires time, expertise, passion and money. We know you appreciate the coverage here. Please help us to continue as an alternative news website by becoming a subscriber or making a donation. To learn more about our subscription options or make a donation, click here.
To Advertise on UtahStandardNews.com, please contact us at: ed@utahstandardnews.com.
Comments - No Responses to “The billion-dollar gamble: Biotech CEO takes a risky second shot at an Alzheimer’s drug”
Sure is empty down here...